Navigation Links
Sanofi New Drug Application for Lixisenatide Accepted for Review by FDA
Date:2/19/2013

PARIS, Feb. 19, 2013 /PRNewswire/ -- Sanofi (EURONEXT : SAN and NYSE : SNY) announced today that the U.S. Food and Drug Administration (FDA) has accepted for review a New Drug Application (NDA) for lixisenatide, the first once-daily prandial GLP-1 receptor agonist for the treatment of adults with type 2 diabetes mellitus. The acceptance of the lixisenatide NDA filing follows the February 1, 2013, European Commission approval of lixisenatide in the European Union.

(Logo: http://photos.prnewswire.com/prnh/20110624/NY25833LOGO

"We are very pleased to announce the FDA acceptance of our submission for lixisenatide in the U.S.," said Pierre Chancel, Senior Vice President, Global Diabetes at Sanofi. "This important milestone is the result of our company's continuing worldwide effort to meet the needs of people living with diabetes, and we look forward to working with the FDA during the review process."

The NDA submission for lixisenatide is based on results from the GetGoal clinical program, which showed that lixisenatide demonstrated significant reductions in HbA1c, a pronounced post-prandial glucose (PPG)-lowering effect and a beneficial effect on body weight in adult patients with type 2 diabetes. GetGoal results also showed that lixisenatide had a favorable safety and tolerability profile in most patients, with mild and transient nausea and vomiting, the most common adverse events observed in the GLP-1 receptor agonist class, and a limited risk of hypoglycemia.

The international GetGoal program included 11 clinical trials involving more than 5,000 patients with type 2 diabetes, with a large number of patients studied to evaluate a GLP-1 receptor agonist in combination with basal insulin (1,250 patients treated with lixisenatide or placebo in three trials).The addition of lixisenatide to basal
'/>"/>

SOURCE Sanofi
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Sanofi Pasteur Presents Pediatric Data on Investigational Quadrivalent Influenza Vaccine
2. Sanofi US Launches Collaborate Activate Innovation Challenge
3. Sanofi Pasteur to add 2D barcode to six more vaccines
4. Sanofi and Regeneron Announce Publication of Phase 2 Results with LDL Cholesterol-Lowering PCSK9 Antibody in the New England Journal of Medicine
5. Sanofi and Regeneron Announce Patient Enrollment in Cardiovascular Outcomes Trial with Antibody to PCSK9 for Hypercholesterolemia
6. Sanofi and T1D Exchange to Launch Worldwide Study to Investigate Factors for Optimal Care for Young People with Diabetes
7. Sanofi Donates $500,000 to Hurricane Sandy for Immediate and Long-Term Relief Efforts
8. Phase II Trial of Sanofi JAK2 Inhibitor in Myelofibrosis Met Primary Endpoint
9. Sanofi Launches Breakthrough Technology for Cardiovascular and Vascular Surgery Procedures
10. Zacks Bull and Bear of the Day Highlights: Smithfield Foods, Logitech International, Sanofi, Isis Pharmaceuticals and Aegerion Pharmaceuticals
11. Zogenix Submits New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Zohydro™ for Treatment of Chronic Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... BOTHELL, Wash. and VANCOUVER ... OGXI ) announced today that it will report ... 13, 2015. Company management will host a conference call ... provide an overview of financial results, clinical development programs ... access the webcast, log on to the Investor Relations ...
(Date:7/30/2015)... July 30, 2015 PTC Therapeutics, Inc. (NASDAQ: ... reported financial results for the second quarter ending June ... many fronts across the organization.  We are excited to ... dystrophy clinical trial ever conducted with topline results expected ... Chief Executive Officer, PTC Therapeutics, Inc. "Translarna is now ...
(Date:7/30/2015)... , July 30, 2015 Tianyin Pharmaceutical ... pharmaceutical company that specializes in the patented biopharmaceutical, modernized ... ingredients (API), provided updates regarding the notice it received ... (the "Exchange") indicating that the Company was below certain ... in Sections 134 and 1101 of the NYSE MKT ...
Breaking Medicine Technology:PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 2PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 3PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 4PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 5PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 6PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 7PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 8PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 9PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 10TPI Provides Update Regarding Non-Compliance with NYSE MKT Continued Listing Requirements 2
... NEW YORK, March 15, 2012 Reportlinker.com ... is available in its catalogue: ... http://www.reportlinker.com/p0578259/Vaccines---Asia.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This market ... on the actual market situation, trends and ...
... that closes a hole in patients, hearts is no more ... a new study published in the March 15 issue of ... the CLOSURE I trial, clinical researchers compared a catheter procedure ... or transient ischemic attacks (TIAs) in patients between 18 and ...
Cached Medicine Technology:Vaccines - Asia 2Landmark Study Finds Expensive Catheter Procedure to Close Hole in Heart No More Effective Than Medical Therapy to Prevent Strokes 2Landmark Study Finds Expensive Catheter Procedure to Close Hole in Heart No More Effective Than Medical Therapy to Prevent Strokes 3
(Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... Ticket Down is a reputable source of ... Women's National Soccer Team will face the Australia Women's National Team in conjunction with their ... score of 5-2. Carli Lloyd from the USA team was awarded the Golden Ball ...
(Date:7/31/2015)... Miami, FL (PRWEB) , ... July 31, 2015 , ... ... die everyday as a direct result of heroin use and eventual overdoses. Thricefold deaths ... is struggling to get a handle on the Sarasota heroin epidemic, which was spurred ...
(Date:7/31/2015)... ... , ... Physical therapy for knee osteoarthritis is an important part of ... the patient from doing what they want or need to do. The patient may have ... stairs. The patient's exercise regime may be limited by the pain in their knee. When ...
(Date:7/31/2015)... Grand Rapids, MI (PRWEB) , ... July 31, ... ... Living Pure Essential Oils are 100% organic, natural, therapeutic-grade oils from ingredients sourced ... founder, Ashley Eilers, explains that “With considerable effort, we have developed the highest-quality ...
(Date:7/31/2015)... ... 31, 2015 , ... “ Crack’em ” was featured on NewsWatch as part ... to consumers. Amanda Forstrom, a technology expert and special reporter for NewsWatch, conducted the ... cooking. , Cooking can be a very messy experience, especially when cracking eggs. Cracking ...
Breaking Medicine News(10 mins):Health News:Cheap USA vs. Australia Tickets at Ford Field in Detroit, MI: Ticket Down Slashes Ticket Prices for Australia vs. USWNT International Friendly Match at Ford Field 2Health News:Sarasota Sufferers Increased Heroin Overdoses and Deaths 2Health News:Sarasota Sufferers Increased Heroin Overdoses and Deaths 3Health News:NYDNRehab Is the First Clinic in NYC to Provide APOS Therapy Based on Results of Complete Gait Analysis 2Health News:NYDNRehab Is the First Clinic in NYC to Provide APOS Therapy Based on Results of Complete Gait Analysis 3Health News:Living Pure Essential Oils takes Therepeutic Essential Oil Market by Storm 2Health News:Make Less Mess while Cooking with Crack’em 2
... 20, 2007 -- A Las Vegas business and Oak Ridge ... risk from dehydration or congestive heart failure. , The task ... was to improve and miniaturize Noninvasive Medical Technologies ZOE, a ... fluid. This is of great importance to members of the ...
... were given Nobel Direct dental implants, the risk of the ... at the Sahlgrenska Academy in Sweden shows that eight per ... was launched in 2004 by Nobel Biocare AB. The implants ... directly into the jawbone without having to first lift up ...
... Holdings Corp. (Nasdaq:,HMSY) today announced that it will present ... held January 7-10, 2008 at the Westin,St. Francis in ... Robert Holster, Chairman and CEO of HMS Holdings Corp., ... Time., A live broadcast of the Company,s presentation ...
... Funding Supports Phase 3 Program for Lead ... Cogentus Pharmaceuticals,Inc. announced today that it ... million to support the clinical development of ... http://www.newscom.com/cgi-bin/prnh/20071112/COGENTUSLOGO ), The Series C ...
... Chichester, UK, December 20, 2007 Wiley-Blackwell, the ... John Wiley & Sons, Inc (NYSE: JWa), (NYSE: ... dedicated to improving healthcare decision-making globally, today announced ... with free one-click access to all residents of ...
... LTC,Financial Partners, the nation,s most experienced long ... size since 2005, to more than 400,field underwriters ... what,s,happening in the long term care insurance field, ... *(Photo Caption: LTC Financial CEO Cameron Truesdell.), ...
Cached Medicine News:Health News:Nevada company, ORNL develop potential lifesaver 2Health News:Gloomy forecast for Nobel Direct after 3 years 2Health News:Cogentus Pharmaceuticals Completes $62.5 Million Private Financing 2Health News:Low-income countries now have free, one-click access to Cochrane Library 2Health News:The Long Term Care Insurance Explosion; January Conference to Celebrate Rapid Growth of LTC Protection and Light Fuse of Further Expansion 2
The Leica M500 OH3 is an advanced surgical microscope used by neurosurgeons. It is a smart system combining the best optical performance available on the market with an innovative and unique stand....
Surgical Loupes...
... MAGNETOM Allegra is the ultimate brain ... been optimized for best image quality ... all in a highly compact design. ... diagnosing stroke, epilepsy, tumor and multiple ...
Signa Profile is built on the Signa foundation to deliver speed & image quality....
Medicine Products: